SAFETY DATA SHEETS

This SDS packet was issued with item: 078944633

N/A



SAFETY DATA SHEET				
Company Name:	Strides Pharma Science Limited	SDS Number: SDS/FD-036-00		
Section 1: Identification				
Product Identifier				
Product name:	Ursodiol Tablets USP 250mg and 500 mg			
Trade name:	Not Applicable			
Product Code No.:	2006153, 2006161, 2006162			
Relevant identified use of th	e substance or mixture and use advis	sed against		
Recommended Use:	Ursodiol suppresses hepatic synthesis and secretion of cholesterol, and inhibits intestinal absorption of cholesterol.			
Restrictions on Use:	Use only as directed.			
Details of the supplier of the	safety data sheet:			
Manufacturer name:	Strides Pharma Science Ltd			
Address:	Strides Pharma Science Limited Strides House, Bilekahalli, Bannerghatta Road, Bangalore, 560076, India.			
Telephone Number- General:	+918067840307/309			
Emergency Telephone Number:	+918067840307/309			
handling this formulated produuse of the product. In this inst or consult their pharmacist or	act in the workplace. It is not intended to ance patients should consult prescribin	nd environmental information for people o provide information relevant to medicinal g information/package insert/product label ation for individual ingredients used during redient.		
Section 2: Hazard Identifica	tion:			
Hazard Classification of chemical mixture	Not classified as Hazardous.			
Hazard Classification of chemical substance	OSHA Regulatory StatusThis chemical is not considered hazardous by the 2012 OSHA HazardCommunication Standard (29 CFR 1910.122)Not a dangerous substance or mixture according to the Globally HarmonizedSystem (GHS)Unknown Acute toxicity, 24.9% of the mixture consists of ingredient(s) ofunknown toxicityOver the counter drugs in their solid form are considered exempt under thecriteria of the Federal OSHA Hazard CommunicationStandard 20 CFR 1910.1200. However, in an industrial setting where acomponent's occupational exposure limit may besurpassed, than can be considered hazardous			

SDS – Ursodiol Tablets USP 250mg and 500mg Page 1 of 10



Signal word	WARNING		
Hazard Statement	Suspected of damaging fertility or the unborn child.		
Additional Hazard Informa	tion		
Short Term:	Not Available		
Long Term:	Not Available		
Label elements			
		ains no substances w hazardous to health	which at their given concentration, are
	Appearance Tab		
	Physical state So		
	Odor No informa Chemical Name		
Precautionary statements	overdose), joint nose and throat i reactions are reported. POVIDONE US irritation. Possibl with skin. Overde cramps, flatulence Chemical Name Medical Conditi obstruction and k components of the	and muscleaches and rritation, inflammati orted with pure mater P: Possible eye, skin e allergic reaction to ose effects from inge e, and fecal impactio : Ursodiol USP: ions Aggravated by nown hypersensitivi ie formulation.	 g (diarrhea has been associated with d pain, back pain, and upper respiratory on and infection; allergic or sensitization ial. Rare cases of skin eruptions have been and gastrointestinal and/or respiratory tract material if inhaled, ingested or in contact estion of large amounts include abdomination. Exposure: Patients with complete biliary ty or intolerance to Ursodiol or any of the sitivity to this medication
Storage/Disposal	Keep containers tightly closed in a dry, cool and well-ventilated place. Store away from incompatible materials		
EU classification	Not available		
US GHS classification	Not available		
Section 3: Composition/Info	ormation on Ingree	dients	
Mixtures:	-		
Composition			
Components (Chemical Name)	Identifiers (CAS No.)	% Composition	Classification according to regulations (US GHS/EU EINECS)
Ursodiol USP	128-13-2	*	204-879-3
Microcrystalline Cellulose ((Avicel PH 101))	9004-34-6	*	232-674-9
Sodium Starch Glycolate	6833-40-9	*	209-150-3



Devidence LISD (K. 20. 22)	0002 20 9	*	228 877 0	
Povidone USP (K-29-32)	9003-39-8		238-877-9	
Sodium Lauryl Sulphate	151-21-3	*	NA	
Tromethamine USP	77-86-1	*	NA	
Polyethylene glycol 3350	25322-68-3	*	NA	
Magnesium Stearate NF	557-04-0	*	NA	
*Percentage composition is n	ot captured due to tra	ade secret.		
Section 4: First aid measure	s			
General advice:	Not applicable			
Inhalation:	Remove to fresh ai	Remove to fresh air.		
Skin contact:	Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.			
Eye contact:	Rinse immediately with plenty of water and seek medical advice.			
Ingestion:	Consult a physician if necessary.			
Most important symptoms a	and effects both acu	te and delayed	:	
Symptoms:	Not available			
Other hazards	Not available			
Indication of immediate me	dical attention and s	special treatme	nt needed	
Notes for the doctor	Not available			
Special treatment	Not available			
Other information	Not available			
Section 5: Fire Fighting Mea	asures			
Extinguishing media				
Suitable Extinguishing Media	Use extinguishing surrounding enviro		re appropriate to local circumstances and the	
Unsuitable Extinguishing Media	None known.			
Specific hazards arising from the chemical	Fire may produce irritating, corrosive and/or toxic gases.			
Explosion data Sensitivity to Mechanical	Not impact sensitiv	/e.		
Impact Sensitivity to Static Discharge	Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.		-	
Protective equipment and precautions for firefighters	-	r self-contained	breathing apparatus pressure-demand,	

SDS – Ursodiol Tablets USP 250mg and 500mg Page 3 of 10



	protective gear			
Section 6: Accidental Relea	se Measures			
Personal precautions, prote				
Personal Precautions:		Use personal protection recommended in Section 8. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.		
Emergency Procedure	See Section 12 for	See Section 12 for additional ecological information.		
Methods and material for c	ontainment and cle	aning up		
Containment/Cleanup measures	Prevent further leakage or spillage if safe to do so. Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly			
Prohibited materials	Not available			
Section 7: Handling and Sto	orage			
Precautions for safe handling	ng			
Patients/Consumers:				
Safe handling:	Avoid contact with skin, eyes or clothing. Avoid generation of dust. Do not eat, drink or smoke when using this product.			
Fire Prevention	Not available			
Environmental precautions	Avoid release to the environment.			
Conditions for safe storage,	including any inco	mpatibilities		
Technical measures and Storage Conditions:	Store at 20°C to 25°C (68°F to 77°F). Dispense in a tight container using a child-resistant closure.			
Special Packaging Materials	Not available			
Section 8: Exposure Contro	ls and personal pro	tection		
Exposure Limits/Guidelines	5			
Component Name	Result	OSHA	Other agency Information	
Ursodiol USP,	OEL 800 ug/m3	No data available	No data available	
Microcrystalline Cellulose (Avicel PH 101)	TWA: 10 mg/m3	TWA: 15 mg/m3 total dust TWA: 5 mg/m3 respirable fraction (vacated) TWA: 15 mg/m3 total dust	NIOSH IDLH : TWA: 10 mg/m3 total dust TWA: 5 mg/m3 respirable dust TWA: 1 mg/m3	
Sodium Starch Glycolate (Type-A)	NA	NA	NA	
Povidone USP (K-29-32)	Not Available	Not Available	Not Available	
Sodium Lauryl Sulphate	Not Available	Not Available	Not Available	

SDS – Ursodiol Tablets USP 250mg and 500mg Page 4 of 10



Tromethamine USP	Not Available	Not Available	Not Available
Polyethylene glycol 3350	Not Available	Not Available	Not Available
Magnesium Stearate NF	TWA: 10 mg/m3 inhalable particulate matter TWA: 3 mg/m3 respirable particulate matter TWA: 10 mg/m3 inhalable particulate matter except stearates of toxic metals TWA: 3 mg/m3 respirable particulate matter except stearates of toxic metals	Not Available	Not Available
Note: Not applicable	L	1	
Exposure Controls			
Engineering Controls	as physical form conducted to det general ventilation conditions. If app other engineering exposure limits. If	and quantity. Site spe ermine the appropriate n should be used. Venti licable, use process enclo controls to maintain ai	terial are dependent on factors, such ecific risk assessments should be exposure control measures. Good ilation rates should be matched to osures, local exhaust ventilation, or rborne levels below recommended been established, maintain airborne
Personal protective equipm	•		
Eye/Face:	No eye protection product. During op		g medical administration of this of the product may be generated,
Skin & Body:	During medical administration of this product, medical latex or nitrile gloves should be worn to avoid absorption of the product. Use appropriate protective clothing for the task (e.g., lab coat, etc.).		
Respiratory protection:	Respiratory protection is generally not needed during routine conditions of use of this product. If respiratory protection is needed, use only respiratory protection authorized under appropriate regional regulations.		
		×	

SDS – Ursodiol Tablets USP 250mg and 500mg Page 5 of 10



Solid Off-white Odorless Not available It melts about 202°C Ursodeoxycholic Acid is slightly soluble in water, freely soluble in alcohol, slightly soluble in acetone and methylene chloride Not available. Not available.	
Odorless Not available It melts about 202°C Ursodeoxycholic Acid is slightly soluble in water, freely soluble in alcohol, slightly soluble in acetone and methylene chloride Not available.	
Not available It melts about 202°C Ursodeoxycholic Acid is slightly soluble in water, freely soluble in alcohol, slightly soluble in acetone and methylene chloride Not available.	
It melts about 202°C Ursodeoxycholic Acid is slightly soluble in water, freely soluble in alcohol, slightly soluble in acetone and methylene chloride Not available.	
It melts about 202°C Ursodeoxycholic Acid is slightly soluble in water, freely soluble in alcohol, slightly soluble in acetone and methylene chloride Not available.	
Ursodeoxycholic Acid is slightly soluble in water, freely soluble in alcohol, slightly soluble in acetone and methylene chloride Not available.	
slightly soluble in acetone and methylene chloride Not available.	
Not available.	
Not available.	
5.0	
Not available.	
activity	
Not defined as Reactive substance	
Stable under normal conditions.	
None under normal processing.	
Aerosol formation.	
None known based on information supplied.	
None known based on information supplied.	
250mg and 500mg	
Page 6 of 10	



Section 11: Toxicological information

Information on toxicological effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

	(Components		
		Acute toxicity		
Components	CAS No	Oral LD50 Dermal LD50 Inhalation LC50	Oral LD50 Dermal LD50 Inhalation LC50	Oral LD50 Dermal LD50 Inhalation LC50
Ursodiol USP	128-13-2	4600 mg/kg (Rat)	4600 mg/kg (Rat)	4600 mg/kg (Rat)
Microcrystalline Cellulose (Avicel PH 101)	9004-34-6	NA	NA	NA
Sodium Starch Glycolate (Type-A)	6833-40-9	> 5 g/kg (Rat) > 2 g/kg (Rabbit) > 5800 mg/m3 (Rat) 4 h	> 5 g/kg (Rat) > 2 g/kg (Rabbit) > 5800 mg/m3 (Rat) 4 h	> 5 g/kg (Rat) > 2 g/kg (Rabbit) > 5800 mg/m3 (Rat) 4 h
Povidone USP (K-29-32)	9003-39-8	100 g/kg (Rat)	= 100 g/kg (Rat)	= 100 g/kg (Rat)
Sodium Lauryl Sulphate	151-21-3	1288 mg/kg [Rat.]	NA	NA
Tromethamine USP	77-86-1	NA	NA	NA
Polyethylene glycol 3350	25322-68-3	Acute: 4000 mg/kg [Rat].	Acute: 20000 mg/kg [Rabbit].	NA
Magnesium Stearate NF	557-04-0	NA	NA	NA
Delayed and immediate effe	cts as well as chron	ic effects from sho	rt and long-term	exposure
Chemical Name Germ cell mutagenicity Carcinogenicity Reproductive Toxicity Effects on or via lactation	Chemical Name Germ cell mutagenicity Carcinogenicity Reproductive Toxicity Effects on or via lactation	Chemical Name Germ cell mutagenicity Carcinogenicity Reproductive Toxicity Effects on or via lactation	Chemical Name Germ cell mutagenicity Carcinogenici ty Reproductive Toxicity Effects on or via lactation	Chemical Name Germ cell mutagenicity Carcinogenicity Reproductive Toxicity Effects on or via lactation
Ursodiol USP, micronized not genotoxic in the Ames	Ursodiol USP, micronized not genotoxic in the	Ursodiol USP, micronized not genotoxic in the	Ursodiol USP, micronized not genotoxic in	Ursodiol USP, micronized not

 $SDS-Ursodiol\ Tablets\ USP\ 250mg\ and\ 500mg$



	Ames and the Chinese hamster bone marrow cell chromosome aberration test.	Ames increased incidence of pheochromocyto mas of the adrenal medulla in females of the highest dose group. On the other hand, in a 32-week rat study, Ursodiol at a daily dose of 240mg/kg (1,440 mg/m2, 2.6 times the maximum recommended	the Ames human dose (based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to Ursodiol.	genotoxic in the Ames
		human dose based on body surface area) suppressed the colonic carcinogenic effect of another known carcinogen azoxymethane.		
POVIDONE USP	information available. Not suspected of being a	information available. Not suspected of being a	information available. Not suspected of being a	information available. Not suspected of being a
Numerical measures of toxicity - Product Information	24.9% of the mixture consists of ingredient(s) of unknown toxicity			
Unknown Acute Toxicity	May cause respiratory irritation.			
ATE mix (oral)	6977 mg/kg			
ATE mix (dermal)	9288 mg/kg			
ATE mix (inhalation- dust/mist)	26.9 mg/l			
Section 12: Feelerical Inform				

Section 12: Ecological Information

SDS – Ursodiol Tablets USP 250mg and 500mg Page 8 of 10



Toxicity	77.47% of the mixture consists of components(s) of unknown hazards to the aquatic environment			
Persistence and degradability	No information available			
Bio accumulative potential	No information available			
Mobility in Soil	No information availab	No information available		
Other adverse effects	No information available			
Section 13: Disposal Consid	lerations			
Product waste	laws and regulations.	Disposal should be in accordance with applicable regional, national and local		
Packaging waste	Do not reuse container. Dispose of contents/containers in accordance with local regulations.			
Section 14: Transport infor	mation			
UN Number	Not available			
UN shipper name	Not available			
Transport hazard class:	Not available			
Environmental hazards	Not available			
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not applicable.			
Section 15: Regulatory Info	prmation			
Carcinogenicity The table b This product contains one or	elow indicates whether ea more substances which a up I), probably carcinoge	ach agency has listed any ingredient as a carcinogen re classified by IARC as enic to humans (Group 2A) or possibly		
Component Name	CAS number	IARC/CERCLA/SARA Emission Reporting		
Microcrystalline Cellulose	9004-34-6	Group 3		
Sodium Starch Glycolate	6833-40-9	Group 3		
Sourum Staren Orycolate	1	Crown 2		
•	9003-39-8	Group 3		
Povidone USP (K-29-32)	9003-39-8 151-21-3	Not Available		
Povidone USP (K-29-32) Sodium Lauryl Sulphate Tromethamine USP				
Povidone USP (K-29-32) Sodium Lauryl Sulphate	151-21-3	Not Available		

SDS – Ursodiol Tablets USP 250mg and 500mg Page 9 of 10



Section 16: Other information	
Reason for revision: (Include Change control number)	New Safety data sheet prepared
Revision date:	NA
Version Number:	00

-